- Administer subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel. The upper arm can also be used if a caregiver administers the injection.
- DO NOT inject ADBRY into skin that is tender, damaged, bruised, or scarred.
- For adults taking the initial loading dose of 600 mg, administer each of the injections (four ADBRY 150 mg injections using prefilled syringes or two ADBRY 300 mg injections using autoinjectors) at different injection sites within the same body area.
- For the subsequent 300 mg doses using the prefilled syringe, administer the two ADBRY 150 mg injections at different injection sites within the same body area, rotating the body area with each subsequent set of injections.
- For the subsequent 300 mg doses using the autoinjector, administer one ADBRY 300 mg injection, rotating the body area with each subsequent injection
- For pediatric patients 12 years of age and older taking the initial loading dose of 300 mg, use prefilled syringes to administer the two ADBRY 150 mg injections at different injection sites within the same body area.
- For the subsequent 150 mg doses, use a prefilled syringe to administer one ADBRY 150 mg injection, rotating the body area with each subsequent injection.
- The ADBRY "Instructions for Use" contains more detailed instructions on the preparation and administration of ADBRY [see Instructions for Use].
Dosage in Adults
The recommended dosage for adults is:
| Initial Loading Dose | Subsequent Dosage |
|---|
| Prefilled syringe | 600 mg (four 150 mg injections) | 300 mg (two 150 mg injections) every other week |
| Autoinjector | 600 mg (two 300 mg injections) | 300 mg (one 300 mg injection) every other week |
After 16 weeks of treatment, for adult patients with body weight below 100 kg who achieve clear or almost clear skin, a dosage of 300 mg every 4 weeks may be considered.
Dosage in Pediatric Patients 12 Years of Age and Older
The recommended dosage for pediatric patients 12 years of age and older is:
| Initial Loading Dose | Subsequent Dosage |
|---|
| Prefilled syringe | 300 mg (two 150 mg injections) | 150 mg (one 150 mg injection) every other week |
Adverse Reactions from Clinical Trials in Adults
The safety of ADBRY was evaluated in a pool of 5 randomized, double-blind, placebo-controlled trials in subjects with moderate-to-severe atopic dermatitis including three phase 3 Eczema Tralokinumab trials (ECZTRA 1, ECZTRA 2, and ECZTRA 3), a dose-finding trial, and a vaccine response trial. The safety population had a mean age of 37 years; 43% of subjects were female, 67% were White, 21% were Asian, and 9% were Black. In terms of co-morbid conditions, 39% of the subjects had asthma, 49% had hay fever, 36% had food allergy, and 21% had allergic conjunctivitis at baseline.
In these 5 atopic dermatitis trials, 1964 subjects were treated with subcutaneous injections of ADBRY, with or without concomitant topical corticosteroids (TCS). A total of 807 subjects were treated with ADBRY for at least 1 year.
ECZTRA 1 and ECZTRA 2 compared the safety of ADBRY monotherapy to placebo through Week 52. ECZTRA 3 compared the safety of ADBRY + TCS to placebo + TCS through Week 32.
Weeks 0 to 16 (ECZTRA 1, ECZTRA 2, and ECZTRA 3):
Table 1 summarizes the adverse reactions identified in the pool of 3 trials (ECZTRA 1, ECZTRA 2, and ECZTRA 3) and that occurred at a rate of at least 1% in the ADBRY 300 mg every other week monotherapy group, and in the ADBRY 300 mg every other week + TCS trial, all at a higher rate than placebo during the first 16 weeks of treatment.
Table 1: Adverse Reactions Occurring in ≥1% of the ADBRY Monotherapy Group or the ADBRY + TCS Group in the Atopic Dermatitis Trials through Week 16| Adverse Reaction | ADBRY Monotherapy Pooled analysis of ECZTRA 1 and ECZTRA 2. | ADBRY + TCS Analysis of ECZTRA 3 where subjects were on background TCS therapy. |
|---|
| ADBRY 300 mg Q2W ADBRY 600 mg at Week 0, followed by 300 mg every other week. | PLACEBO | ADBRY 300 mg Q2W + TCS | PLACEBO + TCS |
|---|
| N=1180 n (%) | N=388 n (%) | N=243 n (%) | N=123 n (%) |
|---|
| Upper respiratory tract infections Upper respiratory tract infections cluster includes upper respiratory tract infection, viral upper respiratory tract infection, pharyngitis, and nasopharyngitis; mainly reported as common cold. | 281 (23.8) | 79 (20.4) | 73 (30.0) | 19 (15.4) |
| Conjunctivitis Conjunctivitis cluster includes conjunctivitis and allergic conjunctivitis. | 88 (7.5) | 12 (3.1) | 33 (13.6) | 6 (4.9) |
| Injection site reactions Injection site reactions cluster includes pain, erythema, and swelling. | 87 (7.4) | 16 (4.1) | 27 (11.1) | 1 (0.8) |
| Eosinophilia Eosinophilia cluster includes eosinophilia and eosinophil count increased. | 17 (1.4) | 2 (0.5) | 3 (1.2) | 0 |
In the monotherapy trials (ECZTRA 1 and ECZTRA 2) through Week 16, the proportion of subjects who discontinued treatment due to adverse reactions was 0.7% in the ADBRY 300 mg every other week group and 0% of the placebo group. In the concomitant TCS trial (ECZTRA 3) through Week 16, the proportion of subjects who discontinued treatment due to adverse reactions was 0.8% in the ADBRY 300 mg every other week +TCS group and 0% of the placebo + TCS group. The most common adverse reactions leading to discontinuation in the ADBRY group compared to the placebo group were injection site reaction (0.3% v. 0) and eosinophilia (0.3% v. 0) in ECZTRA 1 and ECZTRA 2; and injection site reaction (0.4% v. 0) and conjunctivitis (0.4% v. 0) in ECZTRA 3.
Weeks 16-52 (ECZTRA 1 and ECZTRA 2) and Weeks 16-32 (ECZTRA 3):
The safety profile of ADBRY 300 mg every other week with or without TCS during maintenance treatment was consistent with that in the initial 16-week treatment period. In addition, the frequency of adverse reactions with ADBRY 300 mg every other week and every 4 weeks in ECZTRA 1 and ECZTRA 2 was 44% and 34%, respectively, and 43% and 26% with ADBRY 300 mg + TCS every other week and every 4 weeks in ECZTRA 3, respectively.
Adverse Reactions from Clinical Trials in Pediatric Subjects 12 Years of Age and Older
The safety of tralokinumab was assessed in a trial of 289 subjects 12 to 17 years of age with moderate-to-severe atopic dermatitis (ECZTRA 6). Of the 289 subjects, 195 were treated with ADBRY and 94 were treated with matching placebo. The safety profile of ADBRY in these subjects, assessed through the initial treatment period of 16 weeks and the long-term period of 52 weeks, was comparable to the safety profile from trials in adults with atopic dermatitis.
Safety through 268 weeks (ECZTEND)
ECZTEND was an open-label, multicenter, long-term extension trial that further assessed the safety of ADBRY for up to 5 years of treatment in adults and pediatric subjects 12 years of age and older with moderate-to-severe atopic dermatitis who had previously participated in ADBRY trials. The safety data in ECZTEND reflect exposure to ADBRY in 1672 subjects who received 300 mg of ADBRY every two weeks (Q2W), including 1422 exposed for at least 52 weeks, 1184 exposed for at least 104 weeks, 701 exposed for at least 156 weeks, and 33 exposed for at least 264 weeks.
The long-term safety profile was consistent with the safety profile observed up to week 16.
Specific Adverse Reactions
Conjunctivitis and Keratitis
Conjunctivitis, including allergic conjunctivitis, was reported in 7.5% of subjects treated with ADBRY 300 mg every other week (29 events per 100 subject-years of exposure) and in 3.1% of subjects treated with placebo (12 events per 100 subject-years of exposure) in the initial treatment period of up to 16 weeks in the pool of 5 trials. In the ADBRY group, 126 subjects reported 145 events of conjunctivitis, with 114 events resolved at the end of initial treatment period. Conjunctivitis led to discontinuation of treatment in 2 subjects.
During the initial treatment period of the monotherapy trials (ECZTRA 1 and ECZTRA 2), conjunctivitis was reported in 7.7% of subjects treated with ADBRY 300 mg every other week (30 events per 100 subject-years of exposure).
During the maintenance treatment period of the monotherapy trials (ECZTRA 1 and ECZTRA 2) from 16 to 52 weeks, conjunctivitis was reported in 14 (8.9%) subjects treated with ADBRY 300 mg every other week (20 events per 100 subject-years of exposure) and in 10 (6.3%) subjects treated with ADBRY 300 mg every 4 weeks (14 events per 100 subject-years of exposure); and included no serious events, 1 severe event, and 1 event that led to discontinuation. A comparable pattern was seen during the continuation treatment period of an additional 16 weeks in the ADBRY combination trial ECZTRA 3.
Keratoconjunctivitis (including 1 atopic keratoconjunctivitis (0.1%)) was reported in 5 (0.3%) subjects (1.2 events per 100 subject-years of exposure) treated with ADBRY and 0% of subjects treated with placebo during the initial treatment period of up to 16 weeks in the pool of 5 trials. Keratoconjunctivitis was reported as resolved in 2 out of 5 subjects by the end of trials.
Keratitis (including 1 ulcerative keratitis (0.1%)) was reported in 4 (0.2%) subjects treated with ADBRY (0.9 events per 100 subject-years of exposure) and 1 (0.2%) subject (viral keratitis) treated with placebo (0.6 events per 100 subject-years of exposure) during the initial treatment period of up to 16 weeks in the pool of 5 trials. Keratitis was reported as resolved in all but 1 subject by the end of trials. None of the events were serious or led to treatment discontinuation.
During the initial treatment period of the monotherapy trials (ECZTRA 1 and ECZTRA 2), keratitis event rate of 2 per 100 subject-years was reported for ADBRY 300 mg every other week.
During the maintenance treatment period of the monotherapy trials (ECZTRA 1 and ECZTRA 2) from 16 to 52 weeks in the ADBRY 300 mg every other week group, keratitis was reported in 1 (0.6%) subject (ulcerative, severe, resolved after discontinuation) at an exposure-adjusted event rate of 1.2 per 100 subject-years, and keratoconjunctivitis (not serious or severe, resolved, not led to discontinuation) was reported in 3 (1.9%) subjects (3.6 events per 100 subject-years of exposure). No events of keratitis or keratoconjunctivitis was reported in ADBRY every 4 weeks or placebo groups. In the continuation treatment period of ECZTRA 3 (from 16 to 32 weeks), there were no additional events of keratitis reported for subjects randomized to ADBRY 300 mg + TCS.
Eosinophil Counts
ADBRY-treated subjects had a greater mean initial increase from baseline in eosinophil count compared to subjects treated with placebo. The mean and median increases in blood eosinophils from baseline to Week 4 were 190 and 100 cells/mcL, respectively. The increase in the ADBRY-treated subjects declined to baseline level with continued treatment. Eosinophilia (> 5000 cells/mcL) in the initial treatment period of up to 16 weeks was reported in 1.2% in the ADBRY-treated subjects and 0.3% in the placebo-treated subjects. The safety profile for subjects with eosinophilia was comparable to the safety profile for all subjects included in the pool of 5 atopic dermatitis trials.
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADBRY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/adbry-tralokinumab/.
Risk Summary
There are limited data from the use of ADBRY in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Monoclonal antibodies are actively transported across the placenta (see Clinical Considerations).
In an enhanced pre-and post-natal developmental study, no adverse developmental effects were observed in offspring born to pregnant monkeys after intravenous administration of tralokinumab-ldrm during organogenesis through parturition at doses up to 10 times the maximum recommended human dose (MRHD).
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations
Fetal/Neonatal Adverse Reactions
Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses and peaks during the third trimester. Therefore, ADBRY may be present in infants exposed in utero. The potential clinical impact of tralokinumab-ldrm exposure in infants exposed in utero should be considered.
Data
Animal Data
In a pre- and post-natal development study, intravenous doses up to 100 mg/kg tralokinumab-ldrm were administered to pregnant cynomolgus monkeys once every week from gestation day 20 to parturition. No maternal or developmental toxicity was observed at doses up to 100 mg/kg/week (10 times the MRHD on a mg/kg basis of 10 mg/kg/week).
In an enhanced pre- and post-natal development study, intravenous doses up to 100 mg/kg tralokinumab-ldrm (10 times the MRHD on a mg/kg basis of 10 mg/kg/week) were administered to pregnant cynomolgus monkeys once every week from the beginning of organogenesis to parturition. No treatment-related adverse effects on embryofetal toxicity or malformations, or on morphological, functional, or immunological development were observed in the infants from birth through 6 months of age.
Risk Summary
There are no data on the presence of tralokinumab-ldrm in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is present in breast milk. The effects of local gastrointestinal exposure and limited systemic exposure to ADBRY on the breastfed infant are unknown. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for ADBRY and any potential adverse effects on the breastfed child from ADBRY or from the underlying maternal condition.
Immune Response to Non-live Vaccines during Treatment
Immune responses to non-live vaccines were assessed in a trial in which adult subjects with atopic dermatitis were treated with an initial dose of 600 mg (four 150 mg injections) followed by 300 mg every other week administered as subcutaneous injection. After 12 weeks of ADBRY administration, subjects were vaccinated with a combined tetanus, diphtheria, and acellular pertussis vaccine, and a meningococcal vaccine. Antibody responses were assessed 4 weeks later. Antibody response to tetanus, diphtheria, acellular pertussis, and a meningococcal vaccine was similar in tralokinumab-ldrm treated and placebo treated subjects. Immune responses to other vaccines were not assessed.
Absorption
The absolute bioavailability of tralokinumab-ldrm was estimated to be 76%. The time to maximum tralokinumab-ldrm concentrations (tmax) was 5 to 8 days after administration.
Distribution
The volume of distribution of tralokinumab-ldrm was estimated to be approximately 4.2 L.
Elimination
The half-life of tralokinumab-ldrm was 3 weeks and systemic clearance was estimated to be 0.149 L/day.
Metabolism
Tralokinumab-ldrm is expected to be metabolized into small peptides by catabolic pathways.
Specific Populations
Geriatric Patients, Patients with Renal and Hepatic Impairment
No clinically significant differences in the pharmacokinetics of tralokinumab-ldrm were observed based on age (ranged from 18 – 92 years), sex, mild to moderate renal impairment, or mild hepatic impairment. The effect of severe renal impairment or moderate to severe hepatic impairment on the pharmacokinetics of tralokinumab-ldrm is unknown.
Pediatric Patients
In subjects 12 to 17 years of age with atopic dermatitis, the mean (SD) steady-state trough concentration of tralokinumab-ldrm was 59.6 mcg/mL (19.4) and 112.8 mcg/mL (39.2) following administration of ADBRY at 150 mg and 300 mg every other week, respectively.
Body Weight
The exposure of tralokinumab-ldrm decreases with increasing body weight. After 300 mg dose every 4 weeks, the median tralokinumab-ldrm exposure (AUC) of subjects with body weight of above 100 kg is expected to be 1.46-fold lower than that of subjects weighing below 100 kg [see Dosage and Administration (2.2)].
Drug Interaction Studies
Cytochrome P450 Substrates
The effects of tralokinumab on the pharmacokinetics of midazolam (CYP3A4 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), metoprolol (CYP2D6 substrate), and caffeine (CYP1A2 substrate) were evaluated in a clinical trial in 18-20 subjects with moderate to severe atopic dermatitis receiving an initial SC dose of 600 mg followed by 300 mg SC every other week for 14 weeks. No clinically significant changes in the exposure (AUC or Cmax) of the CYP450 substrates after multiple tralokinumab administrations were observed compared to that when administered alone.
Adults
The efficacy of ADBRY was assessed in three randomized, double-blind, placebo-controlled trials [ECZTRA 1 (NCT03131648), ECZTRA 2 (NCT03160885), and ECZTRA 3 (NCT03363854)]. Efficacy was assessed in a total of 1934 subjects 18 years of age and older with moderate-to-severe atopic dermatitis (AD) not adequately controlled by topical medication(s). Disease severity was defined by an Investigator's Global Assessment (IGA) score ≥ 3 in the overall assessment of AD lesions on a severity scale of 0 to 4, an Eczema Area and Severity Index (EASI) score ≥16 on a scale of 0 to 72, and a minimum body surface area (BSA) involvement of ≥10%. At baseline, 58% of subjects were male, 69% of subjects were White, 50% of subjects had a baseline IGA score of 3 (moderate AD), and 50% of subjects had a baseline IGA score of 4 (severe AD). The baseline mean EASI score was 32 and the baseline weekly averaged Worst Daily Pruritus Numeric Rating Scale (NRS) was 8 on a scale of 0-10.
In all three trials, subjects received subcutaneous injections of ADBRY 600 mg or placebo on Day 0, followed by 300 mg every other week or placebo for 16 weeks. Responders were defined as achieving an IGA 0 or 1 ("clear" or "almost clear") or EASI-75 (improvement of at least 75% in EASI score from baseline) at Week 16.
To evaluate maintenance of response in the monotherapy trials (ECZTRA 1 and ECZTRA 2), subjects responding to initial treatment with ADBRY 300 mg every other week were re-randomized to ADBRY 300 mg every other week, ADBRY 300 mg every 4 weeks or placebo every other week for another 36 weeks following first dose administration. Subjects randomized to placebo in the initial treatment period who achieved a clinical response at Week 16 continued to receive placebo every other week for another 36 weeks. Non-responders at Week 16, and subjects who lost clinical response during the maintenance period were placed on open-label treatment with ADBRY 300 mg every other week and optional use of TCS.
In the combination therapy trial (ECZTRA 3), subjects received either ADBRY 300 mg every other week with TCS or placebo with TCS and as needed topical calcineurin inhibitors (TCI) until Week 16. Subjects in the ADBRY 300 mg with TCS group who achieved clinical response at Week 16 were re-randomized to ADBRY 300 mg every other week with TCS or ADBRY every 4 weeks with TCS for another 16 weeks following first dose administration. Subjects in the placebo with TCS group who achieved clinical response at Week 16 continued on placebo with TCS for another 16 weeks. Subjects who did not achieve clinical response at Week 16 received ADBRY 300 mg every other week for another 16 weeks. A mid-potency TCS (i.e., mometasone furoate 0.1% cream) was dispensed at each dosing visit. Subjects were instructed to apply a thin film of the dispensed TCS as needed once daily to active lesions from Week 0 to Week 32 and were to discontinue treatment with TCS when control was achieved. An additional, lower potency TCS or TCI could be used at the investigator's discretion on areas of the body where use of the supplied TCS was not advisable, such as areas of thin skin.
All three trials assessed the primary endpoints of the proportion of subjects with an IGA 0 or 1 at Week 16 and the proportion of subjects with EASI-75 at Week 16. Secondary endpoints included the reduction of Worst Daily Pruritus NRS (weekly average) of at least 4 points on the 11-point itch NRS from baseline to Week 16.
Clinical Response at Week 16 (ECZTRA 1, ECZTRA 2, and ECZTRA 3)
The results of the ADBRY monotherapy trials (ECZTRA 1 and ECZTRA 2) and the ADBRY with TCS trial (ECZTRA 3) are presented in Table 2.
Table 2: Efficacy Results of ADBRY With or Without TCS at Week 16 (ECZTRA 1, ECZTRA 2, and ECZTRA 3) in Subjects with Moderate-to-Severe AD | ECZTRA 1 | ECZTRA 2 | ECZTRA 3 |
|---|
| ADBRY 300 mg every other week | Placebo | ADBRY 300 mg every other week | Placebo | ADBRY 300 mg every other week + TCS | Placebo + TCS |
|---|
Abbreviations: AD = Atopic Dermatitis CI = Confidence Interval. Note: Difference and 95% CI are based on the CMH test stratified by region and baseline IGA score. |
| Number of subjects randomized and dosed (FAS) Full Analysis Set (FAS) includes all subjects randomized and dosed. | 601 | 197 | 577 | 193 | 243 | 123 |
| IGA 0 or 1 Responders was defined as a subject with an IGA 0 or 1 ("clear" or "almost clear"). ,Subjects who received rescue treatment or with missing data were considered as non-responders. | 16% | 7% | 21% | 9% | 38% | 27% |
| Difference from Placebo | 9% | 12% | 11% |
| (95% CI) | (4%, 13%) | (7%, 17%) | (1%, 21%) |
| EASI-75 | 25% | 13% | 33% | 10% | 56% | 37% |
| Difference from Placebo | 12% | 22% | 20% |
| (95% CI) | (6%, 18%) | (17%, 28%) | (9%, 30%) |
| Number of subjects with baseline Worst Daily Pruritus NRS (weekly average) score ≥4 | 594 | 194 | 563 | 192 | 240 | 123 |
| Worst Daily Pruritus NRS (≥4 point reduction) | 20% | 10% | 25% | 9% | 46% | 35% |
| Difference from Placebo | 10% | 16% | 11% |
| (95% CI) | (4%, 15%) | (11%, 21%) | (1%, 22%) |
A higher proportion of subjects in the ADBRY 300 mg every other week arm achieved EASI-90 compared to placebo in the three pivotal trials.
Examination of age, gender, race, body weight, and previous treatment, including immunosuppressants, did not identify differences in response to ADBRY 300 mg every other week among these subgroups.
Monotherapy Trials (ECZTRA 1 and ECZTRA 2) – Maintenance Period (Week 16-52)
In ECZTRA 1, 179 ADBRY 300 mg every other week responders (IGA 0/1 or EASI-75) were re-randomized (and dosed) at Week 16 to ADBRY 300 mg every other week (68 subjects), ADBRY 300 mg every 4 weeks (76 subjects) or placebo (35 subjects). Among these subjects, 39 subjects in ADBRY 300 mg every other week arm, 36 subjects in ADBRY 300 mg every 4 weeks arm and 19 subjects in placebo arm were IGA 0/1 responders at Week 16. Maintenance of IGA 0/1 response at Week 52 was as follows: 20 subjects (51%) in every other week arm, 14 subjects (39%) in every 4 weeks arm and 9 subjects (47%) in the placebo arm. Among the re-randomized subjects, 47 subjects in ADBRY 300 mg every other week arm, 57 subjects in ADBRY 300 mg every 4 weeks arm and 30 subjects in placebo arm were EASI-75 responders at Week 16. Maintenance of EASI-75 response at Week 52 was as follows: 28 subjects (60%) in every other week arm, 28 subjects (49%) in every 4 weeks arm and 10 subjects (33%) in the placebo arm.
In ECZTRA 2, 218 ADBRY 300 mg every other week responders (IGA 0/1 or EASI-75) were re-randomized (and dosed) at Week 16 to ADBRY 300 mg every other week (90 subjects), ADBRY 300 mg every 4 weeks (84 subjects) or placebo (44 subjects). Among these subjects, 53 subjects in ADBRY 300 mg every other week arm, 44 subjects in ADBRY 300 mg every 4 weeks arm and 26 subjects in placebo arm were IGA 0/1 responders at Week 16. Maintenance of IGA 0/1 response at Week 52 was as follows: 32 subjects (60%) in every other week arm, 22 subjects (50%) in every 4 weeks arm and 6 subjects (23%) in the placebo arm. Among the re-randomized subjects, 76 subjects in ADBRY 300 mg every other week arm, 69 subjects in ADBRY 300 mg every 4 weeks arm and 40 subjects in placebo arm were EASI-75 responders at Week 16. Maintenance of EASI-75 response at Week 52 was as follows: 43 subjects (57%) in every other week arm, 38 subjects (55%) in every 4 weeks arm and 8 subjects (20%) in the placebo arm.
Concomitant TCS Trial (ECZTRA 3) – Maintenance Period (Week 16-32)
In ECZTRA 3, 131 ADBRY 300 mg every other week + TCS responders (IGA 0/1 or EASI-75) were re-randomized (and dosed) at Week 16 to ADBRY 300 mg every other week + TCS (65 subjects) or ADBRY 300 mg every 4 weeks + TCS (66 subjects). Among these subjects, 45 subjects in ADBRY 300 mg every other week + TCS arm and 46 subjects in ADBRY 300 mg every 4 weeks + TCS arm were IGA 0/1 responders at Week 16. Maintenance of IGA 0/1 response at Week 32 was as follows: 40 subjects (89%) in every other week arm and 35 subjects (76%) in every 4 weeks arm. Among the re-randomized subjects, 65 subjects in ADBRY 300 mg every other week arm and 62 subjects in ADBRY 300 mg every 4 weeks arm were EASI-75 responders at Week 16. Maintenance of EASI-75 response at Week 32 was as follows: 60 subjects (92%) in every other week arm and 56 subjects (90%) in every 4 weeks arm.
Pediatric Subjects 12 Years of Age and Older
The efficacy of ADBRY monotherapy in pediatric subjects 12 years of age and older was assessed in a multicenter, randomized, double-blind, placebo-controlled trial (ECZTRA 6; NCT03526861) in 289 subjects 12 to 17 years of age with moderate-to-severe AD defined by IGA score ≥ 3 in the overall assessment of AD lesions on a severity scale of 0 to 4, an EASI score ≥ 16 at baseline, and a minimum BSA involvement of ≥10%. Eligible subjects enrolled into this trial had previous inadequate response to topical medication.
A total of 98 subjects received an initial dose of ADBRY 300 mg followed by 150 mg every other week up to Week 16. Subjects who met the clinical response criteria (IGA of 0 or 1 or EASI-75) at Week 16 without the use of rescue medication were re-randomized in a 1:1 ratio to either ADBRY every other week or every 4 weeks up to Week 52, receiving the same dose as during the initial 16-week treatment period. Subjects who did not meet the clinical response criteria at Week 16 or did not maintain the response during the maintenance treatment period, or used rescue medication during the initial treatment period were transferred to open-label treatment with ADBRY 300 mg every other week with optional use of topical corticosteroids. Subjects randomized to placebo in the initial treatment period who achieved a clinical response at Week 16 continued to receive placebo every other week in the maintenance treatment period.
In this trial, the mean subject age was 14.6 years (range: 12 to 17 years), the mean weight was 61.5 kg, 48% of subjects were female, 57% were White, 25% were Asian, and 11% were Black. For ethnicity, 91.3% of subjects identified as non-Hispanic/Latino and 8.7% identified as Hispanic/Latino. At baseline, 53% of subjects had a baseline IGA score of 3 (moderate AD), 47% of subjects had a baseline IGA score of 4 (severe AD), the mean BSA involvement was 51%, and 21% of subjects had received prior systemic immunosuppressants (cyclosporine, methotrexate, azathioprine and mycophenolate). Also, at baseline the mean EASI score was 32, the baseline Adolescent Worst Pruritus NRS score was 8. Overall, 84% of subjects had at least one co-morbid allergic condition; 68% had allergic rhinitis, 51% had asthma, and 57% had food allergies.
The primary endpoints were the proportion of subjects with IGA 0 or 1 at Week 16 ("clear" or "almost clear") and the proportion of patients with EASI-75 (improvement of at least 75% in EASI from baseline) at Week 16. Secondary endpoints included the reduction in itch, as measured by the proportion of subjects with ≥4 point improvement in Adolescent Worst Pruritus NRS from baseline.
The efficacy results at Week 16 for subjects 12 to 17 years of age are presented in Table 3.
Table 3: Efficacy Results of ADBRY Monotherapy in Subjects 12 to 17 Years of Age at Week 16 in Subjects with Moderate-to-Severe AD (ECZTRA 6) | ADBRY 150 mg every other week | Placebo |
|---|
| Abbreviations: AD = Atopic Dermatitis, CI = Confidence Interval |
| Number of subjects randomized and dosed (FAS) Full Analysis Set (FAS) includes all subjects randomized and dosed. | 98 | 94 |
| IGA 0 or 1 Subjects who received rescue treatment from week 2 to week 16 or had missing data were considered non-responders. ,Responder was defined as a subject with IGA 0 or 1 ("clear" or "almost clear" on a 0-4 IGA scale). | 21% | 4% |
| Difference from Placebo | 18% | |
| (95% CI) | (8%, 27%) | |
| EASI-75 | 29% | 6% |
| Difference from Placebo | 23% | |
| (95% CI) | (12%, 33%) | |
| Number of subjects with baseline Worst Daily Pruritus NRS (weekly average) score ≥4 | 95 | 90 |
| Worst Daily Pruritus NRS( ≥4 point reduction) , The percentage is calculated relative to the number of subjects with a baseline value ≥4. | 23% | 3% |
| Difference from Placebo | 20% | |
| (95% CI) | (11%, 29%) | |
In ECZTRA 6, a higher proportion of subjects in the ADBRY 150 mg every other week group achieved EASI-90 compared to placebo.
How Supplied
ADBRY (tralokinumab-ldrm) injection is a sterile, clear to opalescent, colorless to pale yellow solution, supplied in a single-dose prefilled syringe with a 27-gauge, ½ inch needle and a needle guard, or a single-dose autoinjector with a 27-gauge, ½ inch needle.
Each prefilled syringe delivers 150 mg of ADBRY in 1 mL solution (NDC 50222-346-01).
Each autoinjector delivers 300 mg of ADBRY in 2 mL solution (NDC 50222-350-00).
ADBRY is available in pack sizes containing either 2 or 4 prefilled syringes with needle guard or 1 or 2 autoinjectors.
| 150 mg in a 1 mL prefilled syringe – Pack Size | NDC # |
|---|
| Two cartons (multipack) containing 4 prefilled syringes | NDC 50222-346-04 |
| One carton containing 2 prefilled syringes | NDC 50222-346-02 |
| 300 mg in a 2 mL autoinjector – Pack Size | NDC # |
|---|
| One carton containing 2 autoinjectors | NDC 50222-350-02 |
| One carton containing 1 autoinjector | NDC 50222-350-01 |
Administration Instructions
Instruct patients or caregivers:
- to perform the first self-injection under the supervision and guidance of a qualified healthcare provider for proper training in subcutaneous injection technique.
- to inject the full dose of ADBRY.
- to follow sharps disposal recommendations [see Instructions for Use].
Hypersensitivity
Advise patients to discontinue ADBRY and to seek immediate medical attention if they experience any symptoms of systemic hypersensitivity reactions [see Warnings and Precautions (5.1)].
Conjunctivitis and Keratitis
Advise patients to consult their healthcare provider if new onset or worsening eye symptoms develop [see Adverse Reactions (6.1)].
Risk of Infection with Live Vaccines
Instruct patients to inform the healthcare provider that they are taking ADBRY prior to a potential vaccination [see Warnings and Precautions (5.4)].
Pregnancy Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADBRY during pregnancy. Encourage participation and advise patients about how they may enroll in the registry [see Use in Specific Populations (8.1)].
Manufactured by:
LEO Pharma A/S
Industriparken 55
Ballerup, Denmark DK-2750
U.S. License No. 2169
Distributed by:
LEO Pharma Inc.
Madison, NJ 07940, USA
ADBRY® is a registered trademark of LEO Pharma A/S.
© 2025 LEO Pharma Inc. All rights reserved.